A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

被引：0
|
作者：
Jeay, Sebastien [1 ]
Gaulis, Swann [1 ]
Ferretti, Stephane [1 ]
Albrecht, Genevieve [1 ]
Barys, Louise [1 ]
Guthy, Daniel [1 ]
Halilovic, Ensar [2 ]
Ito, Moriko [1 ]
Murakami, Masato [1 ]
Pornon, Astrid [1 ]
Ruetz, Stephan [1 ]
Venkatesan, Kavitha [3 ]
Yu, Jianjun [4 ]
Jensen, Michael [1 ]
Wiesmann, Marion [1 ]
Wuerthner, Jens [5 ]
Graus-Porta, Diana [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
[2] Novartis Oncol Translat Med, Cambridge, MA USA
[3] Novartis Inst Biomed Res, Cambridge, MA USA
[4] Novartis Inst Biomed Res, Emeryville, CA USA
[5] Novartis Oncol Translat Med, Basel, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2909
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2909
引用
收藏
页数：2
相关论文
共 16 条
  • [1] A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097
    Jeay, Sebastien
    Gaulis, Swann
    Ferretti, Stephane
    Bitter, Hans
    Ito, Moriko
    Valat, Therese
    Murakami, Masato
    Ruetz, Stephan
    Guthy, Daniel A.
    Rynn, Caroline
    Jensen, Michael R.
    Wiesmann, Marion
    Kallen, Joerg
    Furet, Pascal
    Gessier, Francois
    Holzer, Philipp
    Masuya, Keiichi
    Wurthner, Jens
    Halilovic, Ensar
    Hofmann, Francesco
    Sellers, William R.
    Porta, Diana Graus
    [J]. ELIFE, 2015, 4
  • [2] NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer
    Ferretti, Stephane
    Berger, Marjorie
    Rebmann, Ramona
    Santacroce, Francesca
    Sterker, Dario
    Jensen, Michael
    Masuya, Keiichi
    Jeay, Sebastien
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [3] Mechanistic study of NVP-CGM097: a potent, selective and species specific inhibitor of p53-Mdm2
    Valat, Therese
    Masuya, Keiichi
    Baysang, Frederic
    Albrecht, Genevieve
    Buschmann, Nicole
    Erdmann, Dirk
    Furet, Pascal
    Gabriel, Tobias
    Gessier, Francois
    Hofmann, Francesco
    Holzer, Philipp
    Kallen, Joerg
    Pissot-Solderman, Carole
    Stutz, Stefan
    Chene, Patrick
    Jeay, Sebastien
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [4] Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
    Holzer, Philipp
    Masuya, Keiichi
    Furet, Pascal
    Kallen, Joerg
    Valat-Stachyra, Therese
    Ferretti, Stephane
    Berghausen, Joerg
    Bouisset-Leonard, Michele
    Buschmann, Nicole
    Pissot-Soldermann, Carole
    Rynn, Caroline
    Ruetz, Stephan
    Stutz, Stefan
    Chene, Patrick
    Jeay, Sebastien
    Gessier, Francois
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (16) : 6348 - 6358
  • [5] Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097
    Meille, C.
    Guerreiro, N.
    Bauer, S.
    Cassier, P.
    Demetri, G.
    Dummer, R.
    Tan, D. S.
    Van Bree, L.
    Ramkumar, T.
    Halilovic, E.
    Jeay, S.
    Jullion, A.
    Hourcade-Potelleret, F.
    Wuerthner, J. U.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1
    Reuther, Clemens
    Heinzle, Vera
    Noelting, Svenja
    Herterich, Sabine
    Hahner, Stefanie
    Halilovic, Ensar
    Jeay, Sebastien
    Wuerthner, Jens U.
    Prada, Elke Tatjana Aristizabal
    Spoettl, Gerald
    Maurer, Julian
    Auernhamme, Christoph J.
    [J]. NEUROENDOCRINOLOGY, 2018, 106 (01) : 1 - 19
  • [7] Integrated profiling of p53 lines identifies differentially responsive p a gene expression signature that predict SAR405838, a potent and selective disruptor of the p53-MDM2 interaction.
    Watters, James
    Rowley, Steve
    Debussche, Laurent
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [8] The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response
    Koeppel, Max
    van Heeringen, Simon J.
    Smeenk, Leonie
    Navis, Anna C.
    Janssen-Megens, Eva M.
    Lohrum, Marion
    [J]. NUCLEIC ACIDS RESEARCH, 2009, 37 (02) : 322 - 335
  • [9] A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors
    Bauer, S.
    Demetri, G.
    Jeay, S.
    Dummer, R.
    Guerreiro, N.
    Tan, D. S.
    Kumar, A.
    Meille, C.
    Van Bree, L.
    Halilovic, E.
    Wuerthner, J. U.
    Cassier, P.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] OVEREXPRESSION OF MDM-2 MESSENGER-RNA AND MUTATION OF THE P53 TUMOR-SUPPRESSOR GENE IN BLADDER-CARCINOMA CELL-LINES
    CHENG, YT
    LI, YL
    WU, JD
    LONG, SB
    TZAI, TS
    TZENG, CC
    LAI, MD
    [J]. MOLECULAR CARCINOGENESIS, 1995, 13 (03) : 173 - 181
12